Review of the currently available systems to obtain platelet related products to treat equine musculoskeletal injuries

Recent Patents on Regenerative Medicine

Volumn 3, Issue 2, 2013, Pages 148-159

  Carmona, Jorge U ^a   López, Catalina ^a   Sandoval, Javier A ^a  

^a UNIVERSIDAD DE CALDAS   (Colombia)

Author keywords

Autologous platelet concentrates; Chronic musculoskeletal diseases; Desmopathy; Devices; Growth factors; Horse; Osteoarthritis; Platelet gel; Platelet rich plasma; Tendinopathy

Indexed keywords

BIOLOGICAL PRODUCT; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET RELATED PRODUCT; PROSTAGLANDIN E2; SOMATOMEDIN B; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

CELL PROLIFERATION; EXTRACELLULAR MATRIX; HORSE; HUMAN; KNEE OSTEOARTHRITIS; LEUKOCYTE COUNT; MESENCHYMAL STROMA CELL; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL INJURY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; SKIN INJURY; TENDINITIS; THROMBOCYTE RICH PLASMA;

EID: 84874021915     PISSN: 22102965     EISSN: 22102973     Source Type: Journal    
DOI: 10.2174/2210296511303020005     Document Type: Review

References (125)

1. Innes JF, Clegg P. Comparative rheumatology: What can be learnt from naturally occurring musculoskeletal disorders in domestic animals? Rheumatology 2010; 49(6): 1030-9.
2. Lui PP, Maffulli N, Rolf C, Smith RK. What are the validated animal models for tendinopathy? Scand J Med Sci Sports 2011; 21(1): 3-17.
3. Dart AJ, Snyder JR, Pascoe JR, Meagher DM, Wilson WD. Prepurchase evaluation of horses: 134 cases (1988-1990). J Am Vet Med Assoc 1992; 201(7): 1061-7.
4. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse-a review. Vet J 2006; 171(1): 51-69.
5. Palmer SE, Genovese R, Longo KL, Goodman N, Dyson S. Practical management of superficial digital flexor tendinitis in the performance horse. Vet Clin North Am Equine Pract 1994; 10(2): 425-81.
6. Dyson SJ. Medical management of superficial digital flexor tendonitis: A comparative study in 219 horses (1992-2000). Equine Vet J 2004; 36(5): 415-9.
7. Carmona J, López C. Tendinopatía del tendón flexor digital superficial y desmopatía del ligamento suspensorio en caballos: Fisiopatología y terapias regenerativas. Arch Med Vet 2011; 43: 203-14.
8. Rossdale PD, Hopes R, Digby NJ, offord K. Epidemiological study of wastage among racehorses 1982 and 1983. Vet Rec 1985; 116(3): 66-9.
9. Koch TG, Berg LC, Betts DH. Current and future regenerative medicine-principles, concepts, and therapeutic use of stem cell therapy and tissue engineering in equine medicine. Can Vet J 2009; 50(2): 155-65.
10. Hraha TH, Doremus KM, McIlwraith CW, Frisbie DD. Autologous conditioned serum: The comparative cytokine profiles of two commercial methods (IRAP and IRAP II) using equine blood. Equine Vet J 2011; 43(5): 516-21.
11. Bosch G, van Schie HT, de Groot MW, Cadby JA, van de Lest CH, Barneveld A, et al. Effects of platelet-rich plasma on the quality of repair of mechanically induced core lesions in equine superficial digital flexor tendons: A placebo-controlled experimental study. J Orthop Res 2010; 28(2): 211-7.
12. Carmona J, López C, Giraldo C. Uso de concentrados autólogos de plaquetas como terapia regenerativa de enfermedades crónicas del aparato musculoesquelético equino. Arch Med Vet 2011; 43: 1-10.
13. Witte TH, Yeager AE, Nixon AJ. Intralesional injection of insulinlike growth factor-I for treatment of superficial digital flexor tendonitis in Thoroughbred racehorses: 40 Cases (2000-2004). J Am Vet Med Assoc 2011; 239(7): 992-7.
14. Nixon AJ, Haupt JL, Frisbie DD, Morisset SS, McIlwraith CW, Robbins PD, et al. Gene-mediated restoration of cartilage matrix by combination insulin-like growth factor-I/interleukin-1 receptor antagonist therapy. Gene Ther 2005; 12(2): 177-86.
15. Godwin EE, Young NJ, Dudhia J, Beamish IC, Smith RK. Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon. Equine Vet J 2012; 44(1): 25-32.
16. Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith CW. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis. J Orthop Res 2009; 27(12): 1675-80.
17. Martinello T, Bronzini I, Maccatrozzo L, Iacopetti I, Sampaolesi M, Mascarello F, et al. Cryopreservation does not affect the stem characteristics of multipotent cells isolated from equine peripheral blood. Tissue Eng Part C Methods 2010; 16(4): 771-81.
18. Textor J. Autologous biologic treatment for equine musculoskeletal injuries: Platelet-rich plasma and IL-1 receptor antagonist protein. Vet Clin North Am Equine Pract 2011; 27(2): 275-98.
19. Busch C, Wasteson Å, Westermark B. Release of a cell growth promoting factor from human platelets. Thromb Res 1976; 8(4): 493-500.
20. Antoniades HN, Scher CD. Radioimmunoassay of a human-serum growth-factor for balb-c-3t3 cells-derivation from platelets. Proc Natl Acad Sci USA 1977; 74(5): 1973-7.
21. Antoniades HN, Scher CD, Stiles CD. Purification of human platelet-derived growth-factor. Proc Natl Acad Sci USA 1979; 76(4): 1809-13.
22. Kaplan DR, Chao FC, Stiles CD, Antoniades HN, Scher CD. Platelet alpha-granules contain a growth-factor for fibroblasts. Blood 1979; 53(6): 1043-52.
23. Assoian RK, Komoriya A, Meyers CA. Transforming growth factor-β in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 1983; 258(11): 7155-60.
24. Clemmons DR, Isley WL, Brown MT. Dialyzable factor in human serum of platelet origin stimulates endothelial cell replication and growth. Proc Natl Acad Sci USA 1983; 80(6): 1641-5.
25. Miyazono K, Okabe T, Ishibashi S. A platelet factor stimulating the proliferation of vascular endothelial cells. Partial purification and characterization. Exp Cell Res 1985; 159(2): 487-94.
26. Schmidt MB, Chen EH, Lynch SE. A review of the effects of insulin-like growth factor and platelet derived growth factor on in vivo cartilage healing and repair. Osteoarthr Cartilage 2006; 14(5): 403-12.
27. Rosenthal AR, Harbury C, Egbert PR, Rubenstein E. Use of a platelet-fibrinogen-thrombin mixture as a corneal adhesive: Experiments with sutureless lamellar keratoplasty in the rabbit. Invest Ophthalmol 1975; 14(11): 872-5.
28. Pearl RM, Wustrack KO, Harbury C, Rubenstein E, Kaplan EN. Microvascular anastomosis using a blood product sealant-adhesive. Surg Gynecol Obstet 1977; 144(2): 227-31.
29. Silverberg GD, Harbury CB, Rubenstein E. A physiological sealant for cerebrospinal fluid leaks. J Neurosurg 1977; 46(2): 215-9.
30. Fischer H. [A method of suture-free anastomosis of nerve transplantation is being reported, using facial nerve as the example (author's transl)]. Laryngol Rhinol Otol (Stuttg) 1979; 58(2): 154-6.
31. Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg 1986; 204(3): 322-30.
32. Whitman DH, Berry RL, Green DM. Platelet gel: An autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg 1997; 55(11): 1294-9.
33. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85(6): 638-46.
34. Anitua E. Plasma rich in growth factors: Preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 1999; 14(4): 529-35.
35. Matras H. The use of fibrin sealant in oral and maxillofacial surgery. J Oral Maxillofac Surg 1982; 40(10): 617-22.
36. Wilson SM, Pell P, Donegan EA. HIV-1 transmission following the use of cryoprecipitated fibrinogen as gel/ adhesive. Transfusion 1991; 31: 51s.
37. Smith, E., Pennie, P., Buzenius, D.K. Centrifuge tube assembly. US6835353 (2004).
38. Mishra, A. Method for treatment of tendinosis using platelet rich plasma. US7608258 (2009).
39. Burnouf, T., Su, C. Clottable concentrate of platelet growth factors and preparation method thereof. US20110027257 (2011).
40. Estereon, A. Assembly, device kit and method for preparing plate (PRP). US20120045424 (2012).
41. Mishra, A. Method of preparing neutrophil-depleted platelet-rich plasma. US20120085651 (2012).
42. Grant WP, Jerlin EA, Pietrzak WS, Tam HS. The utilization of autologous growth factors for the facilitation of fusion in complex neuropathic fractures in the diabetic population. Clin Podiatr Med Surg 2005; 22(4): 561-84.
43. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med 2006; 34(11): 1774-8.
44. Bava ED, Barber FA. Platelet-rich plasma products in sports medicine. Phys Sportsmed 2011; 39(3): 94-9.
45. Taylor DW, Petrera M, Hendry M, Theodoropoulos JS. A systematic review of the use of platelet-rich plasma in sports medicine as a new treatment for tendon and ligament injuries. Clin J Sport Med 2011; 21(4): 344-52.
46. Spakova T, Rosocha J, Lacko M, Harvanova D, Gharaibeh A. Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil 2012. [Epub ahead of print].
47. Filardo G, Kon E, Pereira Ruiz MT, Vaccaro F, Guitaldi R, Di Martino A, et al. Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: Single-versus doublespinning approach. Knee Surg Sports Traumatol Arthrosc 2011; 28: 28.
48. Sanchez M, Anitua E, Azofra J, Aguirre JJ, Andia I. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: A retrospective cohort study. Clin Exp Rheumatol 2008; 26(5): 910-3.
49. Hoksrud AF, Bahr R. Injectable agents derived from or targeting vascularity: Has clinical acceptance in managing tendon disorders superseded scientific evidence? J Musculoskelet Neuronal Interact 2011; 11(2): 174-84.
50. Carmona JU, Arguelles D, Climent F, Prades M. Autologous platelet concentrates as a treatment of horses with osteoarthritis: A preliminary pilot clinical study. J Equine Vet Sci 2007; 27(4): 167-70.
51. Arguelles D, Carmona JU, Climent F, Munoz E, Prades M. Autologous platelet concentrates as a treatment for musculoskeletal lesions in five horses. Vet Rec 2008; 162(7): 208-11.
52. Waselau M, Sutter WW, Genovese RL, Bertone AL. Intralesional injection of platelet-rich plasma followed by controlled exercise for treatment of midbody suspensory ligament desmitis in Standardbred racehorses. J Am Vet Med Assoc 2008; 232(10): 1515-20.
53. Sutter WW, Kaneps AJ, Bertone AL. Comparison of hematologic values and transforming growth factor-beta and insulin-like growth factor concentrations in platelet concentrates obtained by use of buffy coat and apheresis methods from equine blood. Am J Vet Res 2004; 65(7): 924-30.
54. Arguelles D, Carmona JU, Pastor J, Iborra A, Vinals L, Martinez P, et al. Evaluation of single and double centrifugation tube methods for concentrating equine platelets. Res Vet Sci 2006; 81(2): 237-45.
55. McCarrel T, Fortier L. Temporal growth factor release from platelet-rich plasma, trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression. J Orthop Res 2009; 27(8): 1033-42.
56. Schnabel LV, Sonea HO, Jacobson MS, Fortier LA. Effects of platelet rich plasma and acellular bone marrow on gene expression patterns and DNA content of equine suspensory ligament explant cultures. Equine Vet J 2008; 40(3): 260-5.
57. Schnabel LV, Mohammed HO, Miller BJ, McDermott WG, Jacobson MS, Santangelo KS, et al. Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum superficialis tendons. J Orthop Res 2007; 25(2): 230-40.
58. Smith JJ, Ross MW, Smith RK. Anabolic effects of acellular bone marrow, platelet rich plasma, and serum on equine suspensory ligament fibroblasts in vitro. Vet Comp Orthop Traumatol 2006; 19(1): 43-7.
59. Maia L, de Souza MV, Ribeiro Júnior JI, de Oliveira AC, Alves GES, dos Anjos Benjamin L, et al. Platelet-rich plasma in the treatment of induced tendinopathy in horses: Histologic evaluation. J Equine Vet Sci 2009; 29(8): 618-26.
60. Bosch G, Moleman M, Barneveld A, van Weeren PR, van Schie HT. The effect of platelet-rich plasma on the neovascularization of surgically created equine superficial digital flexor tendon lesions. Scand J Med Sci Sports 2011; 21(4): 554-61.
61. Del Bue M, Ricco S, Ramoni R, Conti V, Gnudi G, Grolli S. Equine adipose-tissue derived mesenchymal stem cells and platelet concentrates: Their association in vitro and in vivo. Vet Res Commun 2008; 32(Suppl 1): S51-5.
62. DeRossi R, Coelho AC, Mello GS, Frazilio FO, Leal CR, Facco GG, et al. Effects of platelet-rich plasma gel on skin healing in surgical wound in horses. Acta Cir Bras 2009; 24(4): 276-81.
63. Textor JA, Norris JW, Tablin F. Effects of preparation method, shear force, and exposure to collagen on release of growth factors from equine platelet-rich plasma. Am J Vet Res 2011; 72(2): 271-8.
64. Torricelli P, Fini M, Filardo G, Tschon M, Pischedda M, Pacorini A, et al. Regenerative medicine for the treatment of musculoskeletal overuse injuries in competition horses. Int Orthop 2011; 35(10): 1569-76.
65. Monteiro SO, Lepage OM, Theoret CL. Effects of platelet-rich plasma on the repair of wounds on the distal aspect of the forelimb in horses. Am J Vet Res 2009; 70(2): 277-82.
66. Georg R, Maria C, Gisela A, Bianca C. Autologous conditioned plasma as therapy of tendon and ligament lesions in seven horses. J Vet Sci 2010; 11(2): 173-5.
67. Dunkel B, Bolt DM, Smith RK, Cunningham FM. Stimulusdependent release of tissue-regenerating factors by equine platelets. Equine Vet J 2011; 44(3): 346-54.
68. Castelijns G, Crawford A, Schaffer J, Ortolano GA, Beauregard T, Smith RK. Evaluation of a filter-prepared platelet concentrate for the treatment of suspensory branch injuries in horses. Vet Comp Orthop Traumatol 2011; 24(5): 363-9.
69. Prakash S, Thakur A. Platelet concentrates: Past, present and future. J Maxillofac Oral Surg 2011; 10(1): 45-9.
70. Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med 2011; 39(10): 2135-40.
71. Cho HS, Song IH, Park SY, Sung MC, Ahn MW, Song KE. Individual variation in growth factor concentrations in platelet-rich plasma and its influence on human mesenchymal stem cells. Korean J Lab Med 2011; 31(3): 212-8.
72. Dohan Ehrenfest DM, Bielecki T, Mishra A, Borzini P, Inchingolo F, Sammartino G, et al. In search of a consensus terminology in the field of platelet concentrates for surgical use: Platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. Curr Pharm Biotechnol 2012; 13(7): 1131-7.
73. Kamm JL, Nixon AJ, Witte TH. Cytokine and catabolic enzyme expression in synovium, synovial fluid and articular cartilage of naturally osteoarthritic equine carpi. Equine Vet J 2010; 42(8): 693-90.
74. Montaseri A, Busch F, Mobasheri A, Buhrmann C, Aldinger C, Rad JS, et al. IGF-1 and PDGF-bb suppress IL-1beta-induced cartilage degradation through down-regulation of NF-kappaB signaling: Involvement of Src/PI-3K/AKT pathway. PLoS One 2011; 6(12): e28663.
75. Hosaka Y, Sakamoto Y, Kirisawa R, Watanabe T, Ueda H, Takehana K, et al. Distribution of TNF receptors and TNF receptor-associated intracellular signaling factors on equine tendinocytes in vitro. Jpn J Vet Res 2004; 52(3): 135-44.
76. Hosaka Y, Kirisawa R, Yamamoto E, Ueda H, Iwai H, Takehana K. Localization of cytokines in tendinocytes of the superficial digital flexor tendon in the horse. J Vet Med Sci 2002; 64(10): 945-7.
77. Hosaka Y, Ozoe S, Kirisawa R, Ueda H, Takehana K, Yamaguchi M. Effect of heat on synthesis of gelatinases and pro-inflammatory cytokines in equine tendinocytes. Biomed Res 2006; 27(5): 233-41.
78. Chung HY, Lee EK, Choi YJ, Kim JM, Kim DH, Zou Y, et al. Molecular inflammation as an underlying mechanism of the aging process and age-related diseases. J Dent Res 2011; 90(7): 830-40.
79. Shakibaei M, Buhrmann C, Mobasheri A. Anti-inflammatory and anti-catabolic effects of TENDOACTIVE(R) on human tenocytes in vitro. Histol Histopathol 2011; 26(9): 1173-85.
80. Murayama R, Kobayashi M, Takeshita A, Yasui T, Yamamoto M. MAPKs, activator protein-1 and nuclear factor-kappaB mediate production of interleukin-1beta-stimulated cytokines, prostaglandin E and MMP-1 in human periodontal ligament cells. J Periodontal Res 2011; 46(5): 568-75.
81. van Buul GM, Koevoet WL, Kops N, Bos PK, Verhaar JA, Weinans H, et al. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med 2011; 39(11): 2362-70.
82. Bendinelli P, Matteucci E, Dogliotti G, Corsi MM, Banfi G, Maroni P, et al. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: Mechanisms of NF-κB inhibition via HGF. J Cell Physiol 2010; 225(3): 757-66.
83. Carter CA, Jolly DG, Worden CE, Hendren DG, Kane CJM. Platelet-rich plasma gel promotes differentiation and regeneration during equine wound healing. Exp Mol Pathol 2003; 74(3): 244-55.
84. López C, Carmona J, Samudio I. Use of autologous platelet concentrates as treatment for a scapular fracture and brachial plexus nerve injury produced by a gunshot in a horse. Arch Med Vet 2010; 42: 209-14.
85. Carmona JU, Lopez C. Autologous platelet concentrates as a treatment for shoulder injury in a horse. J Equine Vet Sci 2011; 31(9): 506-510.
86. Dyson S. Sixteen fractures of the shoulder region in the horse. Equine Vet J 1985; 17(2): 104-10.
87. Dutton DM, Honnas CM, Watkins JP. Nonsurgical treatment of suprascapular nerve injury in horses: 8 cases (1988-1998). J Am Vet Med Assoc 1999; 214(11): 1657-9.
88. Iacopetti I, Perazzi A, Ferrari V, Busetto R. Application of plateletrich gel to enhance wound healing in the horse: A case report. J Equine Vet Sci 2012; 32(3): 123-8.
89. Alvarez ME, Lopez C, Giraldo CE, Samudio I, Carmona JU. In vitro bactericidal activity of equine platelet concentrates, platelet poor plasma, and plasma against methicillin-resistant Staphylococcus aureus. Arch Med Vet 2011; 43(2): 155-61.
90. Alvarez ME, Giraldo CE, Carmona JU. Monitoring bacterial contamination in equine platelet concentrates obtained by the tube method in a clean laboratory environment under three different technical conditions. Equine Vet J 2010; 42(1): 63-7.
91. Burton S, Reid-Smith R, McClure JT, Weese JS. Staphylococcus aureus colonization in healthy horses in Atlantic Canada. Can Vet J 2008; 49(8): 797-9.
92. Carmona JU, Lopez C. Comments on Torricelli et al. Regenerative medicine for the treatment of musculoskeletal overuse injuries in competition horses. Int Orthop 2011; 35(11): 1745-48.
93. Carmona J, Argüelles D, Prades M. Niveles de factor de crecimiento transformante beta-3 y óxido nítrico en cuatro concentrados autólogos de plaquetas y plasma derivados de sangre equina. Arch Med Vet 2008; 40: 155-60.
94. Vendruscolo CP, Carvalho AdM, Moraes LF, Maia L, Queiroz DL, Watanabe MJ, et al. Avaliação da eficácia de diferentes protocolos de preparo do Plasma Rico em Plaquetas para uso em Medicina Equina. Pesquisa Vet Brasil 2012; 32: 106-10.
95. Scopus Available at: www.scopus.com/home.url (Accessed on: June 01, 2012).
96. ISI Thomson. Available at: http://wokinfo.com/ (Accessed on: April 11, 2012).
97. Google patents. Available at: https://www.google.com/?tbm=pts&hl=en (Accessed on: May 04, 2012).
98. The United States Patent and Trademark Office. Available at: http://www.uspto.gov/ (Accessed on: June 03, 2012).
99. The European Patent Office. Available at: http://www.epo.org/ (Accessed on: June 03, 2012).
100. Free Patents Online. Available at: http://www.freepatentsonline.com/ (Accessed on: June 04, 2012).
101. World Intellectual Property Organization. Available at: http://www.wipo.int/portal/index.html.en (Accessed on: June 01, 2012).
102. Fresh Patents. com. Available at: http://www.freshpatents.com/ (Accessed on: June 01, 2012).
103. Dechra, putting you first. Available at: http://www.dechraus. com/USProducts/ Products.aspx?pcatid=PROPFIELD465&catid=PROPGR P40&fid=&ProductID=PROD261 (Accessed on: Aphril 27, 2012).
104. Medivet Lab Services. Available at: http://www.medivetlabs.com/store/index.php?main_page=product_info&products_id=9 (Accessed on: April 27, 2012).
105. PulseVet Leadership in Veterinary Regenerative Technology. Available at: http://www.pulsevet.com/veterinary/protec-prpsystem (Accessed on: April 27, 2012).
106. Regenlab. Available at: http://www.regenkit.com/site/index.php/en/veterinary-ca (Accessed on: April 27, 2012).
107. Blasetti, L., Kevy, V. Method for producing platelet rich plasma and/or platelet concentrate. US6398972 (2002).
108. Bereta, R., Grippi, N.A. Systems and methods for preparing autologous fibrin glue. US20090203613 (2009).
109. Gandy, J. Compositions for treating wounds and processes for their preparation. US20060004189 (2006).
110. Turzi, A., DuToit, D.F. Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo. US20090317439 (2009).
111. Bereta, R., Grippi, N.A. Methods and devices for separating liquid components. US7745106 (2010).
112. Dorian, R., Leach, M.D. Apparatus and method for preparing platelet rich plasma and concentrates thereof. US8096422 (2010).
113. Dorian, R., Leach, M.D. Method and apparatus for preparing platelet rich plasma and concentrates thereof. US8133389 (2011).
114. Sengun, M.Z., Parrish, W., Story, B.J., DiMatteo, K., Whittaker, G.R., Fifolt, D.A. Method and device for collecting separate components of whole blood. US20120082652 (2012).
115. Britton, C., Dellinger, A., Limbird, J., Keller, C., Worden, C. Novel wound healing composition not containing bovine-derived activating reagents. US20030007957 (2003).
116. Sumida, E., Kasugai, S., Kazunari, A., Iwasaki, Y. Method for preparing platelet-rich plasma. US20050170327 (2005).
117. Hoemann, C., Buschmann, M., Mckee, M. Composition and method for the repair and regeneration of cartilage and other tissues. US20110086008 (2010).
118. Lim, S., Shanks, S., Maloney, R. Method of treating tissue using platelet-rich plasma in combination with low-level laser therapy. US20100196497 (2010).
119. Evangelista, V. Platelet gel comprising platelet-rich plasma, platelet activator and polymer. US8168230 (2012).
120. Weibrich G, Kleis WKG, Buch R, Hitzler WE, Hafner G. The Harvest Smart PRePTM system versus the Friadent-Schütze platelet-rich plasma kit. Clin Oral Implants Res 2003; 14(2): 233-9.
121. Kaux JF, Le Goff C, Renouf J, Peters P, Lutteri L, Gothot A, et al. Comparison of the platelet concentrations obtained in platelet-rich plasma (PRP) between the GPS™ II and GPS™ III systems. Pathol Biol (Paris) 2011; 59(5): 275-7.
122. Kevy SV, Jacobson MS. Comparison of methods for point of care preparation of autologous platelet gel. J Extra Corpor Technol 2004; 36(1): 28-35.
123. Carmona JU, López C. Questions statistical power of study on release of growth factors from platelet-rich plasma. Am J Vet Res 2011; 72(8): 998-9.
124. McLellan J, Plevin S. Does it matter which platelet-rich plasma we use? Equine Vet J 2011; 23(2): 101-4.
125. Mazzucco L, Balbo V, Cattana E, Guaschino R, Borzini P. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. Vox Sang 2009; 97(2): 110-8.